Department of Critical Care Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing-100 048, China.
Indian J Pharmacol. 2013 Jul-Aug;45(4):359-64. doi: 10.4103/0253-7613.115018.
To investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
A total of 40 male SD rats were equally and randomly divided into four groups: blank group, model group, and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in the treatment group A were intragastrically administered with Huisheng Oral Solution at a dose of 2 ml/100 g body weight (once per 8 hours), 72 hours after carrageenan injection, while those in the treatment group B were administered with Huisheng Oral Solution both 72 hours before and after induction of thrombosis. Blood samples were collected 24, 48, and 72 hours after carrageenan injection for measurements of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), prothrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver, and mesentery samples were taken 72 hours after carrageenan injection for histopathological analysis. The numbers of microthrombi in sections of different tissue samples were counted under a microscope. Blood parameters among each group were compared using the Welch test, the Kruskal-Wallis test, or the SNK test after testing for normality, while the number of microthrombi was compared using the Bonferroni test.
Compared to those in the model group, PT, APTT, and INR were significantly prolonged or increased while FIB was significantly reduced at the majority of time points in the two treatment groups (P < 0.05 for all). The levels of FDPs and D-dimer and PLT counts at the majority of time points were significantly lower (P < 0.05 for all), and the numbers of microthrombi in lung, liver, and mesentery samples were significantly decreased (P < 0.05 for all) in the two treatment groups. The above parameters at the majority of time points showed no significant differences between the two treatment groups.
Huisheng Oral Solution can significantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and microthrombosis, suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis.
探讨回生口服液对血栓形成大鼠模型是否具有抗凝作用。
将 40 只雄性 SD 大鼠等分为空白组、模型组和治疗组 A、B 两组。采用皮下注射角叉菜胶的方法诱导血栓形成,治疗组 A 大鼠在角叉菜胶注射后 72 小时开始灌胃给予回生口服液,剂量为 2 ml/100 g 体重(每 8 小时 1 次),治疗组 B 大鼠在诱导血栓形成前 72 小时开始灌胃给予回生口服液,同时在诱导血栓形成后 72 小时内继续灌胃给予回生口服液。分别于角叉菜胶注射后 24、48、72 小时采集血样,检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、国际标准化比值(INR)、纤维蛋白原(FIB)、凝血酶原活性(PTA)、血小板(PLT)、纤维蛋白降解产物(FDPs)和 D-二聚体。角叉菜胶注射后 72 小时取肺、肝、肠系膜组织样本进行组织病理学分析,在显微镜下计数不同组织切片中的微血栓数量。各组间血液参数采用正态性检验后,用 Welch 检验、Kruskal-Wallis 检验或 SNK 检验进行比较,微血栓数量采用 Bonferroni 检验进行比较。
与模型组相比,在大多数时间点,治疗组 A 和 B 的 PT、APTT 和 INR 明显延长或升高,FIB 明显降低(均 P < 0.05)。在大多数时间点,FDPs 和 D-二聚体以及 PLT 计数水平明显降低(均 P < 0.05),肺、肝、肠系膜组织样本中的微血栓数量明显减少(均 P < 0.05)。在大多数时间点,两组间上述参数无显著差异。
回生口服液可显著改善凝血参数、纤溶参数和 PLT 计数,降低血液高凝状态和微血栓形成,提示其对血栓形成大鼠模型具有抗凝作用。